The Phase II D-PRISM study reported promising efficacy for daratumumab in early multiple myeloma stages, including high-risk MGUS and low-risk smoldering multiple myeloma. The study is framed as an attempt to intervene before progression to symptomatic disease. The update highlights daratumumab’s role as a standard myeloma therapy platform being evaluated in precursor conditions where treatment decisions remain cautious. In D-PRISM, investigators assessed outcomes tied to disease activity and progression risk. For hematology clinicians, this is a key continuation of the “treat earlier” debate in multiple myeloma, where the balance between benefit and overtreatment risk drives trial design. Further follow-up and longer endpoints are likely to determine how clinicians might incorporate daratumumab into management strategies for these early-stage populations.